Biological Aging and Later Type 2 Diabetes in Fatty Liver Disease
Studies whether faster biological aging links to later diabetes in fatty liver.
Plain-language title generated from the registry record
Registry title: Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Key facts
- Where
- Ningbo, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 90 years old?
Source: NCT06984510, who can take part
Where in China
- the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000Ningbo, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ningbo No. 1 Hospital
- Trial code
- NCT06984510
- Record updated
- 4 June 2025
- Original description
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.Read full original descriptionShow less
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.
Inclusion: Abdominal ultrasound data available in annual health check-up records; At least one of the following five metabolic indicators recorded annually:; (1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c).
Exclusion: Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection); Type 2 diabetes mellitus at baseline; Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW); Age <20 or >90 years.